title: Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy.
abstract: OBJECTIVE
  The National Cholesterol Education Program recommends regular physician follow-up and lipid testing to promote adherence with lipid-lowering medications. The objective of this study was to determine whether lipid tests and physician visits after treatment initiation are indeed associated with adherence to statin therapy.
  
  
  METHODS
  A retrospective cohort study was conducted among 19 422 enrolees in a US managed care plan who initiated treatment with a statin between October 1999 and August 2001. Computerised pharmacy, medical and laboratory records were used to study the patterns and predictors of adherence with lipid-lowering therapy for up to 3 years. Adherence was assessed in 3-month intervals with patients considered 'adherent' if > or = 80% of days were covered by lipid-lowering therapy.
  
  
  RESULTS
  In the first 3 months, 40% of patients had follow-up lipid tests and only 21% had dyslipidaemia visits (14% had both). Those receiving such care were substantially more likely to be adherent in subsequent intervals. Compared with those without follow-up, the relative odds of adherence were 1.42 and 1.27 for patients with one or more lipid test and one or more dyslipidaemia visit, respectively (95% confidence intervals [CI] 1.33, 1.50 and 1.16, 1.39). Patients who received a follow-up visit and lipid test were 45% more likely to be adherent (95% CI 1.34, 1.55). Similar associations were observed when lipid tests and dyslipidaemia visits occurred later in therapy.
  
  
  CONCLUSIONS
  Early and frequent follow-up by physicians--especially lipid testing--was associated with improved adherence to lipid-lowering therapy. A randomised prospective study is needed to determine whether this relationship is causal.
authors.affiliation: ValueMedics Research, LLC, Arlington, Virginia, USA. josh.benner@ValueMedics.com
authors.forename: Joshua S
authors.initials: JS
authors.lastname: Benner
authors.forename: Jonothan C
authors.initials: JC
authors.lastname: Tierce
authors.forename: Christie M
authors.initials: CM
authors.lastname: Ballantyne
authors.forename: Cheryl
authors.initials: C
authors.lastname: Prasad
authors.forename: Michael F
authors.initials: MF
authors.lastname: Bullano
authors.forename: Vincent J
authors.initials: VJ
authors.lastname: Willey
authors.forename: John
authors.initials: J
authors.lastname: Erbey
authors.forename: David S
authors.initials: DS
authors.lastname: Sugano
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015331:Cohort Studies; D003327:Coronary Disease / Q000188:drug therapy; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000188:drug therapy*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010349:Patient Compliance / Q000706:statistics & numerical data*; D010817:Physician-Patient Relations; D010818:Practice Patterns, Physicians'; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D014481:United States
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids